Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
The branded generics business is spread in India and more than 30 emerging countries across Africa, South East Asia, West Asia, and CIS. In India it has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.
Emerging markets are the major contributors in its branded generic business where it is present across Asia and Africa.

It is gradually building a meaningful presence in the US market with select product portfolio, which include complex technology products to get the competitive advantage in the market place. It expects US market to be its key growth driver in the coming years.

Company’s Institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.
Ajanta Pharma employs around 7,000 people worldwide. The company operates 7 manufacturing facilities in India, 2 of which have been successfully approved by the US FDA. The company’s R&D center has a team of over 750 scientists.
For more information about the company, click http://www.ajantapharma.com/

Objects of the Buyback
i) Distribute surplus funds to shareholders and thereby enhance their overall return.
ii) Improve financial ratios like Earnings per share , Return on assets and Return on Equity

Ajanta Pharma Buyback Details
Issue Period Feb 3, 2022 – Feb 16, 2022
Security Name Ajanta Pharma Limited
Issue Type Tender Offer
Issue Size (Shares) 0.11 Crores
Issue Size (Amount) Rs 285.60 Crores
Buyback Price Rs 2550 per share
Face Value Rs 2 per share
Listing At BSE, NSE

Ajanta Pharma Buyback Issue Timetable
Offer Opens On Feb 3, 2022
Offer Closes On Feb 16, 2022
Record Date Jan 14, 2022
Last Date for receipt of Tender Forms Feb 16, 2022
Finalisation of Buyback Acceptance Feb 24, 2022
Last Date for settlment of bids Feb 25, 2022
Last Date for Extinguishment of Shares Mar 4, 2022

Buyback Ratio

Category : Reserved Category for Small Shareholders
30 Equity Shares out of every 151 shares held on the record date.
Category : General .. for all other Eligible Shareholders
1 Equity Shares out of every 91 shares held on the record date.

Registered office of Ajanta Pharma Limited
‘Ajanta House’, 98 Govt Industrial Area, Chark
Kandivli (West),
Mumbai – 400 067, India

Ajanta Pharma Lead Manager(s)
Vivro Financial Services Private Limited
Registered Broker
Pravin Ratilal Share and Stock Brokers Limited

Ajanta Pharma Buyback Registrar
Link Intime India Private Ltd

Chanakya’s Observations: